Menopause—Biology, consequences, supportive care, and therapeutic options

Cell, Journal Year: 2023, Volume and Issue: 186(19), P. 4038 - 4058

Published: Sept. 1, 2023

Language: Английский

---

Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision

British journal of surgery, Journal Year: 2024, Volume and Issue: 111(5)

Published: May 1, 2024

Hereditary adenomatous polyposis syndromes, including familial and other rare increase the lifetime risk of colorectal cancers.

Language: Английский

---

Menopause on the market: navigating the dualities of care and empowerment

Journal of Marketing Management, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 28

Published: Feb. 3, 2025

Language: Английский

---

Adipocyte Metabolism and Health after the Menopause: The Role of Exercise

Nutrients, Journal Year: 2023, Volume and Issue: 15(2), P. 444 - 444

Published: Jan. 14, 2023

Postmenopausal women represent an important target population in need of preventative cardiometabolic approaches. The loss estrogen following the menopause eliminates protections against metabolic dysfunction, largely due to its role health and function adipose tissue. In addition, some studies associate with reduced physical activity, which could potentially exacerbate deleterious risk profile accompanying menopause. Meanwhile, exercise has adipocyte-specific effects that may alleviate adverse impact through menopausal transition period beyond. Exercise thus remains best therapeutic agent available mitigate menopause-associated dysfunction represents a vital behavioral strategy prevent decline this population.

Language: Английский

---

Adipose-derived stem cells promote the repair of chemotherapy-induced premature ovarian failure by inhibiting granulosa cells apoptosis and senescence

Stem Cell Research & Therapy, Journal Year: 2023, Volume and Issue: 14(1)

Published: April 11, 2023

Abstract Background Chemotherapeutic drugs, particularly alkylating cytotoxics such as cyclophosphamide (CTX), play an important role to induce premature ovarian failure (POF). Hormone replacement therapy (HRT) is a widely used treatment improve hormone secretion. However, the long-term HRT increases risk of breast cancer and cardiovascular disease are attracting concerns. Therefore, there urgent need develop safe effective for POF. Method Adipose-derived stem cells (ADSCs) were isolated identified from human adipose tissue. For POF modeling, CTX intraperitoneal injected into CTX-acute group, CTX-chronic + ADSCs group rats; transplantation, transplanted rats through tail-vein. The control with PBS. effects modeling transplantation determined by estrous cycle analysis, histopathological immunohistochemical staining apoptosis-related marker. To evaluate ADSC on granulosa in vitro, CTX-induced senescent KGN co-cultured ADSCs, senescent-related marker expression was investigated immunofluorescent staining. Results In vivo studies revealed that reduced apoptosis secretion follicle-stimulating hormone. number total follicles, primordial primary mature follicles anti-Müllerian estradiol (E2) also increased ADSCs. improved transplantation. Histopathological analysis showed CTX-damaged microenvironment Furthermore, TUNEL indicated decreased vitro assay demonstrated markedly attenuated senescence cell. Mechanistically, both experiments proved suppressed activation PI3K/Akt/mTOR axis. Conclusion Our experiment single injection high-dose less damaging chemotherapeutic strategy than continuous low-dose CTX, tail-vein potential approach promote restoration

Language: Английский

---

Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause

Menopause The Journal of The North American Menopause Society, Journal Year: 2024, Volume and Issue: 31(4), P. 342 - 354

Published: March 11, 2024

Abstract Importance Vasomotor symptoms (VMS) affect many postmenopausal persons and impact sleep quality of life. Objective This systematic review examines the literature describing safety efficacy neurokinin-3 receptor antagonists approved in development for with VMS. Evidence Review A search MEDLINE, EMBASE, International Pharmaceutical Abstracts was conducted using terms permutations antagonist, elinzanetant, fezolinetant, osanetant. Inclusion criteria reporting on or osanetant; studies participants identifying as female; full record English; primary were applied. Abstract-only records excluded. Extracted data synthesized to allow comparison reported study characteristics, outcomes, events. Eligible evaluated risk bias via Cochrane Risk Bias 2 tool randomized Grading Recommendations Assessment, Development Evaluation system used. neither funded nor registered. Findings The returned 191 records; 186 screened after deduplication. met by six controlled trials (RCT), four two elinzanetant. One a post hoc analysis fezolinetant RCT. An additional identified outside database search. Three RCT demonstrated reduction VMS frequency/severity, improvement Menopause-Specific Quality Life scores, at weeks 4 12 compared placebo without serious adverse elinzanetant also showed improvements frequency severity. All eight through treatment-emergent events; most common events COVID-19, headache, somnolence, gastrointestinal. Each had low bias. There is strong certainty evidence per system. Conclusions Relevance Because high-quality supporting these agents may be an effective option mild women seeking nonhormone treatment

Language: Английский

---

Administration route of progesterone in combined HRT as a predictor of breast cancer risk in menopausal women: a review

Primary Health Care, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

---

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled relating to MHT's clinical indications, efficacy, safety explore the limitations data. Patients review focuses on MHT‐related outcomes women natural‐timed captured within observational studies, RCTs, data from pivotal meta‐analyses reviews. Measurements Available published are scrutinized. notably lacking not adequately represented MHT trials, such as those socioeconomic adversity, significant comorbidities, minority ethnic backgrounds, highlighted deliberated. Results impact differs significantly between demographics. Current consensus recommendations for emphasize importance tailoring type, route, dose, duration individual needs risk/benefit ratio through shared decision‐making. can change over time. support its benefits treating symptoms potential window opportunity midlife benefit skeletal health. Limitations highlight health inequalities underscores need further research. Conclusions This recommends tailored use well‐defined recognizing value symptom relief many women. may be used long outweigh risks, There is insufficient long‐term some contemporary cohorts accessing practice.

Language: Английский

---

Epimedin C promotes mitochondrial transfer and delays thymus atrophy in 4-VCD induced mimetic-menopausal mice

Phytomedicine, Journal Year: 2025, Volume and Issue: 139, P. 156452 - 156452

Published: Feb. 3, 2025

Language: Английский

---

Harnessing omics data for drug discovery and development in ovarian aging

Human Reproduction Update, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Ovarian aging occurs earlier than the of many other organs and has a lasting impact on women's overall health well-being. However, effective interventions to slow ovarian remain limited, primarily due an incomplete understanding underlying molecular mechanisms drug targets. Recent advances in omics data resources, combined with innovative computational tools, are offering deeper insight into complexities aging, paving way for new opportunities discovery development. This review aims synthesize expanding multi-omics data, spanning genome, transcriptome, proteome, metabolome, microbiome, related from both tissue-level single-cell perspectives. We will specially explore how analysis these emerging datasets can be leveraged identify novel targets guide therapeutic strategies slowing reversing aging. conducted comprehensive literature search PubMed database using range relevant keywords: age at natural menopause, premature insufficiency (POI), diminished reserve (DOR), genomics, transcriptomics, epigenomics, DNA methylation, RNA modification, histone proteomics, metabolomics, lipidomics, single-cell, genome-wide association studies (GWAS), whole-exome sequencing, phenome-wide (PheWAS), Mendelian randomization (MR), epigenetic target, machine learning, artificial intelligence (AI), deep multi-omics. The was restricted English-language articles published up September 2024. Multi-omics have uncovered key driving including damage repair deficiencies, inflammatory immune responses, mitochondrial dysfunction, cell death. By integrating researchers critical regulatory factors across various biological levels, leading potential Notable examples include genetic such as BRCA2 TERT, like Tet FTO, metabolic sirtuins CD38+, protein BIN2 PDGF-BB, transcription FOXP1. advent cutting-edge technologies, especially technologies spatial provided valuable insights guiding treatment decisions become powerful tool aimed mitigating or As technology advances, integration AI models holds more accurately predict candidate convergence offers promising avenues personalized medicine precision therapies, tailored Not applicable.

Language: Английский

---